On April 1, 2026, cbdMD, Inc. filed an 8-K report detailing the approval of its 2025 Equity Compensation Plan by shareholders on March 30, 2026. The plan aims to incentivize employees, officers, directors, and consultants by allowing them to acquire a proprietary interest in the company through stock options and other stock-based awards. Initially, the plan reserves 891,316 shares of common stock for issuance. Additionally, the plan includes an 'evergreen formula' that will automatically increase the number of shares available for issuance by 2% of the total shares outstanding each year, starting in 2026, up to a maximum of 300,000 shares.

The approval of the 2025 Plan is significant as it aligns with the company's strategy to attract and retain talent in a competitive market. Furthermore, the plan's structure is designed to enhance employee engagement and align their interests with those of shareholders. The company also disclosed that T. Ronan Kennedy, the CEO and CFO, received a restricted stock award of 445,000 shares, contingent upon the approval of the 2025 Plan.

During the same shareholder meeting, several other proposals were voted on, including the appointment of Cherry Bekaert LLP as the independent registered public accounting firm and the approval of a reverse stock split ranging from 1-for-2 to 1-for-10. All proposals received majority approval, indicating strong shareholder support for the company's governance and strategic direction. The overall positive reception of these proposals suggests a favorable outlook for cbdMD, Inc. as it continues to navigate the evolving landscape of the cannabis industry.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.